SMARCA4 and neuroblastoma: Here, we show that elevated SMARCA4 expression corresponds strongly to poor outcomes for neuroblastoma patients, whereas elevated expression of SMARCA1 correlates to good outcome, suggesting antagonist roles in neuroblastoma for members of this gene family.